Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 2, 2003, Pages 225-230

  Breitz, Hazel ^a   Wendt, Richard ^b   Stabin, Michael ^c   Bouchet, Lionel ^d   Wessels, Barry ^e  

^a Poniard Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

166Ho DOTMP; Dosimetry; Skeletal Targeted Radiotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONATE HO 166; RADIOPHARMACEUTICAL AGENT; SARCOLYSIN; UNCLASSIFIED DRUG;

BLADDER IRRIGATION; BLADDER WALL; BONE; BONE MARROW; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSIMETRY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG UPTAKE; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MODEL; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NEPHROTOXICITY; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; STEM CELL TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0037729040     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803765036391     Document Type: Conference Paper

References (17)

1. Huang, YW: Current Drug Therapy for Multiple Myeloma. Drugs. 57(4):485-506, 1999.
2. Alexanian R, and Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 330:484-489, 1994.
3. Barlogie B, Hall R, Zander A, Dicke K, and Alexanian R: High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67:1298-1301, 1986.
4. Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M, Monto, R, and Wilson H: Combination chemotherapy for multiple myeloma. Cancer 30:382-389, 1972.
5. Attal, M, Huguet F, and Schlaifer D: Intensive combined therapy for previously untreated aggressive myeloma. Blood 79:1130-1136, 1992.
6. Attal M, and Harousseau J: Standard Therapy Versus Autologous Transplantation in Multiple Myeloma. Hematology/Oncology Clinics of North America 11:133-147, 1997.
7. Giralt S, Champlin R, Alexanian D et al. Results of a Phase I/II trial with 166Ho-DOTMP plus high dose chemotherapy in patients with multiple Myeloma. Eighth International Myeloma Proceedings. 40-41, 2001.
8. Loevinger RL, Budinger TF, et al. MIRD Primer for Absorbed dose calculations. New York. Society of Nuclear Medicine. 1988.
9. Eckerman K and Stabin M. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. ICRP Publication 70. Health Phys. 78(2):199-214, 2000.
10. Basic Anatomical and Physiological Data for use in Radiological Protection: The Skeleton. Annals of ICRP. New York, Pergamon. 1995 ICRP Publication 23.
11. Report of the task group on reference man: anatomical, physiological and metabolic characteristics. Annals of ICRP. New York, Pergamon Press. 1975.
12. ICRP Publication 53. Radiation Dose to Patients from Radiopharmaceuticals. Annals of ICRP. New York, Pergamon Press. 1987.
13. Thomas S, Stabin M, Chen and Samaratunga. MIRD Pamphlet No. 14 Revised: A Dynamic Urinary Bladder Model for Radiation Dose Calculations. J Nucl Med 40 (4) 102S-123S; 1999.
14. Bergsagel DE: Plasma Cell Myeloma, in Hematology, 4th Ed., Williams WJ, Beutler E, Erslev AJ, Lichtman MA, Edit., McGraw-Hill, New York, 1990, 1114-1140.
15. Kasiske BL, Umen AJ. The influence of age, sex, race, and body habitus on kidney weight in humans. Arch Pathol Lab Med 1986 Jan; 110(1):55-60
16. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiation Oncology Biol Phys 18:1261-1269; 1990.
17. Dale RG. Dose-rate effects in targeted radiotherapy. Phys. Med. Biol. 41: 1871-1884; 1996.